Caixa Capital Riscthe "la Caixa" group's venture capital manager for innovative companies in the early stages, which had 4 investment vehicles specialising in Biotechnology, Industry and ICT, has launched a new Biotechnology fund together with the CDTI.
Experience in the biotechnology sector
La Caixa already had, Caixa Capital BioMedThe company, a private equity with a total committed capital of €23 million to invest in medical technology, new therapies, diagnostics and services. Since its creation in 2011, the vehicle has invested 14m in 13 companies, which have raised more than private investment national and international support for their business projects.
Transactions carried out
Among the companies that have received funding are STAT-DIAGNOSTICA which designs, develops, manufactures and markets a system that integrates molecular diagnostic and immunoassay tests in a device and cartridges. Together with Caixa Capital BioMed also participated in the series B round, which raised €17M. Kurma Life Sciences Partners, Ysios Capital, Axis, Idinvest, Boehringer Ingelheim Venture Fund.
Another recent operation, carried out in February 2014, involves Genmedica Therapeutics.
The Catalan biopharmaceutical company Genmedica Therapeutics has completed a financing round 1M to fund the development of a drug for the treatment of type 2 diabetes. The capital increase has been mainly covered by the company's own shareholders, including Caixa Capital Risc.
Caixa Invests Biomed
The new fund, Caixa Innvierte BioMed II, which has the support of the CDTI and will have an investment volume of €35M will enable Caixa Capital BioMed to complete its investment period and focus on the value creation of its investee companies.
"The creation of the new fund shows us the interest that Caixa Capital Risc , which sees an opportunity in the Biotechnology sector, and according to the latest report of the Spanish Association of Biocompanies (ASEBIO), Spain ranks ninth in the world and fifth at European level in scientific production, a sector that in 2013 accounted for 7.15% of Spain's GDP. In 2011, there were 3,025 companies related to biotechnology activities in the country. There is a strong culture of spin-off in the sector, with between 10 and 12 new companies being created every year from public institutions," says Diego Gutierrez, the group's expert in alternative finance. Abra Invest.
Other posts that may interest you
Latest investments in "disease diagnostics
Since 2007, US private equity has invested 2400MM$ in the healthcare sector.
Healthcare does not feel the impact of the crisis
If you want to know more or if you think we can help you, do not hesitate to contact us.
EN 
ES